AVAX Technologies, Inc. (AVXT)
AVAX Technologies, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Philadelphia, PA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $6,894. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -1038.8%. Its beta of -55.48 implies it has historically moved less than the broad market.
AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a potential treatment for non-small cell lung cancer. Established in 1990, the Philadelphia, Pennsylvania-based entity initially operated as Walden Laboratories, Inc. before adopting its current name, AVAX Technologies, Inc., in March 1996.
AVAX Technologies, Inc. is most often compared with the following Healthcare names: